The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The comprehensive methylation landscape of metastatic castration-resistant prostate cancer (mCRPC) identifies new phenotypic subtypes: Results from the West Coast Prostate Cancer Dream Team (WCDT).
 
Eric Jay Small
Stock and Other Ownership Interests - Fortis; Harpoon Therapeutics
Honoraria - Janssen
Consulting or Advisory Role - Beigene; Fortis; Janssen Oncology; Teon Therapeutics; Tolero Pharmaceuticals
Research Funding - Janssen (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Janssen
 
Shuang Zhao
Employment - PFS Genomics (I)
Leadership - PFS Genomics (I)
Patents, Royalties, Other Intellectual Property - Patent applications jointly between the University of Michigan OTT and GenomeDx Biosciences. Patent applications jointly between the University of Michigan OTT and Celgene. (Inst)
Other Relationship - GenomeDx
 
William S. Chen
No Relationships to Disclose
 
Haolong Li
No Relationships to Disclose
 
Adam Foye
No Relationships to Disclose
 
Martin Sjöström
No Relationships to Disclose
 
Jun Jie Hua
No Relationships to Disclose
 
Rahul Raj Aggarwal
Honoraria - Clovis Oncology
Consulting or Advisory Role - AstraZeneca; Dendreon; Janssen
Research Funding - Abbvie (Inst); Amgen (Inst); Cancer Targeted Technology (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Xynomic Pharma (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - Xynomic Pharma
 
Joshi J. Alumkal
Consulting or Advisory Role - Janssen Biotech
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); Gilead Sciences (Inst); Novartis (Inst); Zenith Epigenetics (Inst)
 
Tomasz M. Beer
Stock and Other Ownership Interests - Arvinas; Salarius Pharmaceuticals
Consulting or Advisory Role - Arvinas; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; GlaxoSmithKline; Janssen Biotech; Merck; Novartis; Pfizer; Tolero Pharmaceuticals
Research Funding - Alliance Foundation Trials (Inst); Astellas Pharma (Inst); Boehringer Ingelheim (Inst); Corcept Therapeutics (Inst); Endocyte (Inst); Harpoon Therapeutics (Inst); Janssen Research & Development (Inst); Medivation (Inst); Sotio (Inst); Theraclone Sciences (Inst); Zenith Epigenetics (Inst)
 
Martin Gleave
Stock and Other Ownership Interests - OncoGenex
Honoraria - Astellas Pharma; Bayer; Genova Diagnostics; Janssen; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Genova Diagnostics; Janssen; Pfizer; Sanofi
Research Funding - Astellas Pharma; Bayer; Janssen
Patents, Royalties, Other Intellectual Property - OncoGenex - OGX-011, OGX-427; ST-CP; ST-POP
 
Matthew Rettig
Consulting or Advisory Role - Johnson & Johnson
Speakers' Bureau - Bayer; Johnson & Johnson
Research Funding - Johnson & Johnson (Inst); Medivation/Astellas (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a patent for novel inhibitors of the N-terminal domain of the AR. There are NO commercial partnerships as of yet.
Travel, Accommodations, Expenses - Johnson & Johnson
 
Owen Witte
Leadership - Allogene Therapeutics; Breakthrough Properties; Kronos Bio
Stock and Other Ownership Interests - Allogene Therapeutics; Kronos Bio; SOFIE; Trethera
Consulting or Advisory Role - Allogene Therapeutics; Breakthrough Properties; Kronos Bio
Patents, Royalties, Other Intellectual Property - US Patent No: 62/660,864 Title: TREATMENT OF PROSTATE CANCER USING CHIMERIC ANTIGEN RECEPTORS Filed: April 20, 2018 Inventors: Owen N. Witte, John K. Lee, Nathanael J. Bangayan F&W Ref.: 33484-40213/US UCLA Ref.: 2018-571-1; Your Reference: 2019-008-2 / CIT 8139-PCT Our Reference: 30435.0364WOU1 Utility: PCT Application Serial No. PCT/US19/49484 Filed on September 4, 2019 Title: COMPOSITION OF NY-ESO-1-SPECIFIC T CELL RECEPTORS RESTRICTED ON MULTIPLE MAJOR HISTOCOMPATIBIL; Your Reference: 2020-152-1 Our Reference: 30435.0388USP1 Utility: Provisional Application Serial No. 62/895,382 Filed on September 3, 2019 Title: METHOD TO CLONE HUMAN T CELL RECEPTORS FROM SINGLE LYMPHOCYTES BASED ON FUNCTIONAL PROFILING Inventor(s)
Travel, Accommodations, Expenses - Allogene Therapeutics; Kronos Bio
 
Primo Lara
Consulting or Advisory Role - CellMax Life; Janssen; Merck; Pfizer
Research Funding - Aragon Pharmaceuticals (Inst); Incyte (Inst); Janssen Biotech (Inst); Merck (Inst); Pharmacyclics (Inst); Taiho Pharmaceutical (Inst); TRACON Pharma (Inst)
 
Arul Chinnaiyan
No Relationships to Disclose
 
Chris Maher
No Relationships to Disclose
 
David A. Quigley
No Relationships to Disclose
 
Felix Y Feng
Leadership - PFS Genomics
Stock and Other Ownership Interests - Nutcracker Therapeutics, Inc.; PFS Genomics; SerImmune
Honoraria - Genentech
Consulting or Advisory Role - Bayer; Blue Earth Diagnostics; Celgene; EMD Serono; Genzyme; Janssen Biotech; Medivation/Astellas
Research Funding - Zenith Epigenetics
Patents, Royalties, Other Intellectual Property - I helped develop a molecular signature to predict radiation resistance in breast cancer, and this signature was patented by the University of Michigan, my employer. It is in the process of being licensed to PFS Genomics, a company that I helped found. (Inst)